AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$6.37 USD
-1.28 (-16.73%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.58 +0.21 (3.30%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.37 USD
-1.28 (-16.73%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.58 +0.21 (3.30%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
AngioDynamics (ANGO) Q1 Earnings Beat Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 100.00% and -2.32%, respectively, for the quarter ended August 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AngioDynamics (ANGO) Q1 Earnings Expected to Decline
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics (ANGO) Down 8.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics (ANGO) Q4 Earnings Miss, Revenues Top Estimates
by Zacks Equity Research
AngioDyamics (ANGO) gains from solid segmental contributions in fourth-quarter fiscal 2019.
AngioDynamics (ANGO) Lags Q4 Earnings Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -3.85% and 3.72%, respectively, for the quarter ended May 2019. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics (ANGO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics Divests NAMIC Portfolio to Medline Industries
by Zacks Equity Research
The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.
AngioDynamics IDE Application for NanoKnife Gets FDA Nod
by Zacks Equity Research
AngioDynamics' (ANGO) pilot study is intended to support the approval of a future PMA in the United States.
Why Is AngioDynamics (ANGO) Down 12.1% Since Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics' (ANGO) Q3 Earnings & Revenues Lag Estimates
by Zacks Equity Research
Despite strength in the VIT business, AngioDynamics (ANGO) exited third-quarter fiscal 2019 on a tepid note, with both earnings and revenues missing estimates.
AngioDynamics Gets FDA Nod to Begin NanoKnife DIRECT Study
by Zacks Equity Research
AngioDynamics' (ANGO) launches AngioDIRECT.com for enrolling participants as part of the DIRECT clinical study.
AngioDynamics (ANGO) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -13.64% and -2.44%, respectively, for the quarter ended February 2019. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics' Latest FDA Approval to Boost Oncology Unit
by Zacks Equity Research
AngioDynamics' (ANGO) OARtrac is the first of its kind radiation dose monitoring platform.
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avanos (AVNS) Q4 Earnings Beat, Revenues Miss, Shares Down
by Zacks Equity Research
Avanos (AVNS) registers solid growth in the Chronic Care and Pain Management segments in Q4.
AMN Healthcare (AMN) Q4 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) Q4 results get a boost from Nurse and Allied Solutions and Other Workforce Solutions segments.
Cooper Companies' (COO) Q1 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Strong performance by Cooper Companies' (COO) CSI and CVI segments drove the top line in first-quarter fiscal 2019.
GNC Holdings' (GNC) Q4 Earnings Miss Estimates, Margins Fall
by Zacks Equity Research
GNC Holdings' (GNC) international segment registers revenue growth in the fourth quarter.
Here's Why You Should Invest in AngioDynamics Stock Now
by Zacks Equity Research
Expanding customer base of the NanoKnife platform is likely to fortify AngioDynamics' (ANGO) foothold in the Medical Instruments space.
HMS Holdings' (HMSY) Q4 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Strong performance in Analytical Services drove HMS Holdings' (HMSY) performance in Q4.
PRA Health's (PRAH) Q4 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
PRA Health (PRAH) gains from solid segmental contributions in Q4.
Inogen (INGN) Q4 Earnings Beat Estimates, Rental Revenues Up
by Zacks Equity Research
Inogen (INGN) gains from solid direct-to-consumer revenues in Q4; strong business-to-business revenues in the United States.
OPKO Health (OPK) Reports Loss in Q4, Misses on Revenues
by Zacks Equity Research
OPKO Health (OPK) witnesses sluggishness in the Products revenues segment in Q4. However, contribution from RAYALDEE has been significant in the quarter.
Penumbra (PEN) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Penumbra (PEN) sees strength across all segments in Q4.
Bio-Rad (BIO) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Bio-Rad's (BIO) solid revenue growth in geographies like Americas and Asia Pacific in Q4 buoys optimism.